loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for (4''R)-22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    (4''R)-22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 98,243Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Menarini's Tenkasi (Oritavancin) Receives Approval in Europe
    Menarini's Tenkasi (Oritavancin) Receives Approval in Europe

    08 Jun 2023

    // EMA

    https://www.ema.europa.eu/en/documents/overview/tenkasi-previously-orbactiv-epar-medicine-overview_en.pdf

    EMA
    08 Jun 2023
    Share Share
    Melinta Announces Two Key Milestones for KIMYRSA
    Melinta Announces Two Key Milestones for KIMYRSA

    20 Sep 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210920005513/en

    BUSINESSWIRE
    20 Sep 2021
    Share Share
    Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin)
    Melinta Therapeutics Announces Commercial Availability of KIMYRSA™ (oritavancin)

    07 Jul 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210707005030/en

    BUSINESSWIRE
    07 Jul 2021
    Share Share
    Melinta Therapeutics Announces FDA Approval of KIMYRSA™
    Melinta Therapeutics Announces FDA Approval of KIMYRSA™

    15 Mar 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210315005224/en

    BUSINESSWIRE
    15 Mar 2021
    Share Share
    Melinta won FDA approval for skin infection fighter Kimyrsa
    Melinta won FDA approval for skin infection fighter Kimyrsa

    15 Mar 2021

    // Fraiser Kansteiner FIERCEPHARMA

    https://www.fiercepharma.com/pharma/melinta-bouncing-back-from-bankruptcy-lands-fda-approval-for-speedy-bacterial-skin-infection

    Fraiser Kansteiner FIERCEPHARMA
    15 Mar 2021
    Share Share
    Menarini Group announces a commercial agreement for Vabomere, Orbactiv & Minocin
    Menarini Group announces a commercial agreement for Vabomere, Orbactiv & Minocin

    11 Oct 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/menarini-group-anuncia-un-acuerdo-comercial-para-vabomere-orbactiv-y-minocin-en-68-pa%C3%ADses-861609999.html

    PR NEWSWIRE
    11 Oct 2018
    Share Share